Solid Phase Peptide Synthesis and Analysis for Exendin-4

China Biotechnology

2011, Vol. 31

Issue (02): 69-73 DOI:

Solid Phase Peptide Synthesis and Analysis for Exendin-4

LIU Yan-jie, JI Hong, LIN Lu-xia, ZANG Xue-zhang, SONG Chang-zheng, RONG Hai-qin

Shandong Institute of Endocrine and Metabolic Diseases, Shandong Academy of Medical Science, Jinan 250062, China

Download:

HTML

PDF(664KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Exendin-4 is the first-approved drug of the incretin mimetic family, which acts like the naturally occurring hormone GLP-1 in vivo. Exendin-4 decreases fasting and postprandial plasma glucose levels. Exendin-4 may play a role in enhancing glucose-dependent stimulation of insulin secretion, and maintaining of β-cell mass by promotion of β-cell proliferation and neogenesis, and inhibiting of β-cell apoptosis. This experiment studied the standard Fmoc strategy solid phase synthesis of Exendin-4. Using NMP as the coupling solvent, HOBt/DIC as the coupling reagent, AIM as the containing reagent. Synthesized peptides were clearaged by TFA/Phenol/TIS, and identified by high performance liquid chromatography and quadrupole time of flight LC/MS. The yield of pure Exendin-4 was 21% with a purity of 99.4%. Using the SRB method to measure the bioassay of Exendin-4 cell regeneration experiment. It is an influential research into the therapy of type 2 diabetes mellitus.

Key words： Exendin-4 Solid phase peptide synthesis Type 2 diabetes mellitus

Received: 02 November 2010 Published: 18 February 2011

ZTFLH:

Q819

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yan-Jie
	JI Hong
	LIN Lu-Xia
	ZANG Hua-Zhang
	SONG Zhang-Zheng
	RONG Hai-Qin

Cite this article:

LIU Yan-jie, JI Hong, LIN Lu-xia, ZANG Xue-zhang, SONG Chang-zheng, RONG Hai-qin. Solid Phase Peptide Synthesis and Analysis for Exendin-4. China Biotechnology, 2011, 31(02): 69-73.

URL:

https://manu60.magtech.com.cn/biotech/ OR https://manu60.magtech.com.cn/biotech/Y2011/V31/I02/69

[1] Kolterman O G, Kim D D, Shen L, et al. Pharmacokinetics, pharmacodynamics and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm, 2005, 62 : 173-181.
[2] Kwon D Y, Kim Y S, Ahn I S,et al. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J Pharmacol Sci, 2009, 111 (4) : 361-371.
[3] Derosa G, Maffioli P, Salvadeo S A T, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technology and Therapeutics, 2010, 12 (3) : 233-240.
[4] Bunck M C, Diamant M, Corner A, et al. One-year treatment with Exenatide improves cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care, 2009, 32 : 762-768.
[5] 孙玉昆,伍登熙,朱志勇,等.促胰岛素分泌肽衍生物. 中国,1363559,2002-08-14. Sun Y K, Wu D X, Zhu Z Y, et al. Insulinotropic hormone secretion peptide derivative. China, 1363559, 2002-08-14.
[6] Kent S B, Merrifield R B. Chemical mechanism to account for artifactual formation of shortened peptides with free alpha-amino groups in solid phase peptide synthesis. Int J Pept Res,1983, 22(1):57-65.
[7] Louis A C, Grace Y H. 9-Fluoenylmethoxycarbonyl amino-protecting group. J Org Chem, 1972,37(22):3404-3409.
[8] 周国华, 罗国安, 朱敏生. 基体辅助激光解吸质谱法在生物大分子质量研究中的应用. 药学学报, 1998,33(4):290-295. Zhou G H, Luo G A, Zhu M S.Acta Pharmaceutica Sinica, 1998,33(4):290-295.

[1]	SHAO Yu, QU Guo-long, JIN Jing, WANG Wei, TAN Jun-jie, KAN Nai-peng, LI Yu-xia, LIU Gang, CHEN Hui-peng. *Rapid Assembly of Long-term HSA/Exendin 4 Fusion Protein via* BglBrick Method**[J]. China Biotechnology, 2014, 34(4): 59-64.

Viewed

Full text

Abstract

Cited

Shared

Discussed